Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $36.25.

Several equities analysts recently commented on the company. Cantor Fitzgerald assumed coverage on Nuvectis Pharma in a research note on Monday, August 24th. They issued an “overweight” rating on the stock. Lucid Cap Mkts raised Nuvectis Pharma to a “strong-buy” rating in a research report on Tuesday, September 1st. HC Wainwright restated a “buy” rating and issued a $39.00 target price on shares of Nuvectis Pharma in a research note on Thursday, September 24th. Zacks Research cut Nuvectis Pharma from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 5th. Finally, Loop Capital set a $40.00 price target on Nuvectis Pharma in a research note on Tuesday, September 1st.

View Our Latest Analysis on Nuvectis Pharma

Nuvectis Pharma Stock Performance

Shares of NVCT stock opened at $19.20 on Wednesday. The firm has a market cap of $660.29 million, a price-to-earnings ratio of -10.16 and a beta of -0.21. Nuvectis Pharma has a 52 week low of $5.77 and a 52 week high of $29.27. The firm’s 50-day simple moving average is $20.41 and its two-hundred day simple moving average is $15.29.

Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.78). Analysts forecast that Nuvectis Pharma will post -1.89 earnings per share for the current year.

Institutional Investors Weigh In On Nuvectis Pharma

Several institutional investors have recently added to or reduced their stakes in NVCT. Legal & General Group Plc bought a new position in Nuvectis Pharma during the second quarter worth about $31,000. Bank of America Corp DE raised its position in shares of Nuvectis Pharma by 10.2% in the first quarter. Bank of America Corp DE now owns 14,847 shares of the company’s stock valued at $115,000 after purchasing an additional 1,377 shares during the period. Avalon Trust Co bought a new stake in shares of Nuvectis Pharma in the second quarter valued at approximately $257,000. Deutsche Bank AG purchased a new stake in shares of Nuvectis Pharma during the 2nd quarter valued at approximately $310,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Nuvectis Pharma during the 2nd quarter valued at approximately $676,000. 96.77% of the stock is owned by hedge funds and other institutional investors.

About Nuvectis Pharma

(Get Free Report)

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with serious diseases, particularly cancer. Its research and development programs target molecular pathways that may be relevant to specific tumor types. The company’s pipeline includes NXP800, an investigational small-molecule drug designed to inhibit the heat shock factor 1 pathway, and NXP900, an investigational inhibitor of the SRC and YES1 kinases. Nuvectis has studied NXP800 in ovarian cancer and is developing NXP900 for solid tumors; both remain investigational and are not approved medicines.

See Also

Analyst Recommendations for Nuvectis Pharma (NASDAQ:NVCT)

Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.